Vanderbilt awarded $4.4 million by the Michael J. Fox Foundation

by Bill Snyder

A drug discovery team at Vanderbilt University Medical Center led by Jeffrey Conn., Ph.D., has been awarded a $4.4 million "LEAPS" grant by the Michael J. Fox Foundation for Parkinson’s Research to jump-start development of a new class of Parkinson’s disease drugs.

"Dopamine replacement therapies have long been considered the ‘gold standard’ of Parkinson’s treatment. But they lose efficacy over time, alleviate only some of Parkinson’s disease symptoms, and cause side effects that can be as debilitating as the disease itself," said Katie Hood, CEO of the Michael J. Fox Foundation.

"Patients don’t think this status quo is good enough and neither does our foundation," Fox said in a prepared statement. "Dr. Conn and his colleagues are aiming to bring about a 180-degree turn in Parkinson’s disease treatment by developing an entirely new class of drugs that would bypass the dopamine system altogether."

The funding was awarded under the foundation’s 2007 LEAPS (Linked Efforts to Accelerate Parkinson’s Solutions) initiative.

In previous work, Conn’s group showed that increasing the activity of a specific glutamate receptor, mGluR4, alleviated symptoms of Parkinson’s in an animal model.

In further work supported by the foundation’s Target Validation initiative, his team identified molecules that increase mGluR4 activity. During the next three years, the researchers will use a combination of medicinal chemistry, molecular biology, and animal studies to engineer these molecules into a compound that can be clinically tested for use as a drug that could provide sustained symptomatic relief.

"At that point," Conn said, "we may partner with a large pharmaceutical company."

Early animal studies suggest that some of the molecules may slow progression of Parkinson’s disease. While there are no guarantees that humans will respond in the same way, if they do, "it would be the first-ever treatment to be successful in slowing progression," he said.

Conn, a professor of Pharmacology, directs the Vanderbilt Program in Drug Discovery. His LEAPS team includes:

David Weaver, Ph.D., director of the Vanderbilt Institute of Chemical Biology (VICB) high-throughput screening facility and of new leads discovery in the Program in Drug Discovery, who will oversee the high-throughput screening to identify initially promising lead compounds;

Colleen Niswender, Ph.D., head of the molecular pharmacology team in the Program in Drug Discovery, who will screen lead compounds in cell-based assays to determine which hold the most promise to move on to testing in animal models;

Carrie Jones, Ph.D., head of the in-vivo and behavioral pharmacology group in the Program in Drug Discovery, who will spearhead the screening of lead compounds in rodent behavior models of Parkinson’s disease;

Yoland Smith, Ph.D., professor of Neurology at the Yerkes National Primate Research Center at Emory University, who will oversee testing of the most promising lead compounds in the final preclinical phase of the project; and

Craig W. Lindsley, Ph.D., who directs the medicinal chemistry core in the Program in Drug Discovery, the Chemistry Center in Vanderbilt’s Molecular Libraries Screening Center Network and the VICB synthesis core.

Lindsley will hold ultimate responsibility for optimizing the compound that will be tested in the clinic.


Financial Planning for the LGBTQ+ community

The new year has arrived. For many people, that means making resolutions and thinking of ways they can do better in the coming year and beyond. Money management and financial planning are often very popular resolutions and goals, but most financial advice tends to be aimed at heterosexual couples who want to grow their family and raise children.

But, what if your life goals are different? What if you don’t receive the same protection under the current laws as hetero couples?
What if you don’t want to have kids?

Keep reading Show less
Photo courtesy of Joe Eats World

Slane Irish Whiskey bottles

Disclaimer: My trip was provided courtesy of a press trip but all opinions about the trip and events are my own. Please note there are affiliate links and at no additional cost to you, I may earn a commission if you make a purchase.

Keep reading Show less
Photo by Tim Mossholder on Unsplash

Mental Health for LGBTQ+ Aging Adults

Queer elders have made a big impact on the world. Queer folks over the age of 65 were around during the Stonewall Movement in the 1960s and may have even campaigned to improve the rights and freedoms of LGBTQ+ people around the world.

But, as queer elders enter later life, they may need to find new ways to protect and preserve their mental health.

Keep reading Show less